Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
by christian bundgaard, translated by catherine brett
On Tuesday the EMA announced that it had started assessing whether Bavarian Nordic’s smallpox vaccine could be used to combat the ongoing monkeypox outbreak in Europe.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA starts assessment of Bavarian Nordic's monkeypox vaccine
For subscribers
US authorities expand monkeypox vaccine plan
For subscribers
